gemfibrozil has been researched along with Hyperlipoproteinemias in 32 studies
Hyperlipoproteinemias: Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months." | 9.08 | A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995) |
| " We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia." | 9.08 | Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. ( Angelin, B; Bröijersen, A; Eriksson, M; Hjemdahl, P; Wiman, B, 1996) |
| "Nineteen adult patients with type III hyperlipoproteinemia (HLP) and homozygosity for apolipoprotein (apo) E2 were treated with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor simvastatin (20 or 40 mg per day) alone or in combination with the fibrate derivative gemfibrozil (450 mg per day) during a 30-week outpatient study." | 9.07 | The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. ( Eichinger, M; Feussner, G; Ziegler, R, 1992) |
| "To compare the efficacy and tolerability of Gemfibrozil and Bezafibrate in patients with hyperlipoproteinemia, types IIa, IIb and IV." | 9.07 | [Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. ( Bergmann, S; Fücker, K; Gross, P; Hanefeld, M; Hora, C; Julius, U, 1992) |
| "The effects of gemfibrozil on serum lipids and apolipoproteins were investigated in 60 male survivors of myocardial infarction (MI) (age range 29-48 years, mean 44)." | 9.05 | Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. ( Ehnholm, C; Kaukola, S; Mälkönen, M; Manninen, V, 1981) |
| "Gemfibrozil treatment produced a marked reduction in plasma triglyceride (51%, P = 0." | 6.66 | Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. ( Cheung, AK; Ellis-Benigni, K; Groggel, GC; Wilson, DE, 1989) |
| "In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months." | 5.08 | A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995) |
| " We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia." | 5.08 | Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. ( Angelin, B; Bröijersen, A; Eriksson, M; Hjemdahl, P; Wiman, B, 1996) |
| "Nineteen adult patients with type III hyperlipoproteinemia (HLP) and homozygosity for apolipoprotein (apo) E2 were treated with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor simvastatin (20 or 40 mg per day) alone or in combination with the fibrate derivative gemfibrozil (450 mg per day) during a 30-week outpatient study." | 5.07 | The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. ( Eichinger, M; Feussner, G; Ziegler, R, 1992) |
| "To compare the efficacy and tolerability of Gemfibrozil and Bezafibrate in patients with hyperlipoproteinemia, types IIa, IIb and IV." | 5.07 | [Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. ( Bergmann, S; Fücker, K; Gross, P; Hanefeld, M; Hora, C; Julius, U, 1992) |
| "The effects of gemfibrozil on serum lipids and apolipoproteins were investigated in 60 male survivors of myocardial infarction (MI) (age range 29-48 years, mean 44)." | 5.05 | Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. ( Ehnholm, C; Kaukola, S; Mälkönen, M; Manninen, V, 1981) |
| "Treatment with gemfibrozil, compared with placebo, significantly reduced fasting plasma triglycerides (difference from placebo +/- SE; -50." | 2.71 | Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. ( Berneis, KK; Rizzo, M; Superko, HR; Williams, PT; Wood, PD, 2005) |
| "Gemfibrozil treatment produced a marked reduction in plasma triglyceride (51%, P = 0." | 2.66 | Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. ( Cheung, AK; Ellis-Benigni, K; Groggel, GC; Wilson, DE, 1989) |
| "In a single-blind study the lipid-lowering drug gemfibrozil was compared at fixed dosage of 1600 mg daily with placebo and other drugs (mainly clofibrate) over a nine month period in 33 patients with hyperlipidaemia." | 2.65 | The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. ( Nye, ER; Sutherland, WH; Temple, Wa, 1980) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| "Eruptive and tubero-eruptive xanthomas arising at the site of previous minor skin injury are described in two patients with type IV and type III hyperlipidemia, respectively." | 1.27 | Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports. ( Davignon, J; Roederer, G; Xhignesse, M, 1988) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| " It was concluded that the long-term administration of this compound did not show adverse effects on the hepatocyte in hyperlipoproteinemia." | 1.26 | Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. ( Buchanan, RA; De La Iglesia, FA; Lewis, JE; Marcus, EL; McMahon, G, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (56.25) | 18.7374 |
| 1990's | 11 (34.38) | 18.2507 |
| 2000's | 3 (9.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Superko, HR | 1 |
| Berneis, KK | 1 |
| Williams, PT | 1 |
| Rizzo, M | 1 |
| Wood, PD | 1 |
| Pickering, JE | 2 |
| Samuel, P | 1 |
| Glueck, C | 1 |
| De La Iglesia, FA | 1 |
| Lewis, JE | 1 |
| Buchanan, RA | 1 |
| Marcus, EL | 1 |
| McMahon, G | 1 |
| Nye, ER | 1 |
| Sutherland, WH | 1 |
| Temple, Wa | 1 |
| Nash, DT | 1 |
| Kaukola, S | 1 |
| Manninen, V | 2 |
| Mälkönen, M | 1 |
| Ehnholm, C | 1 |
| Ohrvall, M | 1 |
| Lithell, H | 1 |
| Johansson, J | 1 |
| Vessby, B | 1 |
| Bröijersen, A | 1 |
| Eriksson, M | 1 |
| Wiman, B | 1 |
| Angelin, B | 1 |
| Hjemdahl, P | 1 |
| Nestel, P | 1 |
| Simons, L | 1 |
| Barter, P | 1 |
| Clifton, P | 1 |
| Colquhoun, D | 1 |
| Hamilton-Craig, I | 1 |
| Sikaris, K | 1 |
| Sullivan, D | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Fruchart, JC | 1 |
| Brewer, HB | 1 |
| Leitersdorf, E | 1 |
| Henry, K | 1 |
| Melroe, H | 1 |
| Huebesch, J | 1 |
| Hermundson, J | 1 |
| Simpson, J | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Schweitzer, M | 1 |
| Tessier, D | 1 |
| Vlahos, WD | 1 |
| Leiter, L | 1 |
| Collet, JP | 1 |
| McQueen, MJ | 1 |
| Harvey, L | 1 |
| Alaupovic, P | 1 |
| Feussner, G | 1 |
| Eichinger, M | 1 |
| Ziegler, R | 1 |
| Julius, U | 1 |
| Hora, C | 1 |
| Gross, P | 1 |
| Fücker, K | 1 |
| Bergmann, S | 1 |
| Hanefeld, M | 1 |
| Glueck, CJ | 1 |
| Oakes, N | 1 |
| Speirs, J | 1 |
| Tracy, T | 1 |
| Lang, J | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Szostak, WB | 1 |
| Hunninghake, DB | 1 |
| Ceska, R | 1 |
| Sobra, J | 1 |
| Groggel, GC | 1 |
| Cheung, AK | 1 |
| Ellis-Benigni, K | 1 |
| Wilson, DE | 1 |
| Huttunen, JK | 1 |
| Frick, MH | 1 |
| Heinonen, OP | 1 |
| Heinsalmi, P | 1 |
| Mänttäri, M | 1 |
| Romo, M | 1 |
| Roederer, G | 1 |
| Xhignesse, M | 1 |
| Davignon, J | 2 |
| Blum, CB | 1 |
| Levy, RI | 2 |
| Schaefer, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gemfibrozil and Hyperlipoproteinemias
| Article | Year |
|---|---|
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.
Topics: Animals; Cholesterol, LDL; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hydroxymethylg | 1998 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; | 1990 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom | 1985 |
14 trials available for gemfibrozil and Hyperlipoproteinemias
| Article | Year |
|---|---|
Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
Topics: Adult; Aged; Biomarkers; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hy | 2005 |
Clinical results with gemfibrozil.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Gemfibrozil; Humans; Hype | 1983 |
Influence of gemfibrozil on high-density lipoproteins.
Topics: Animals; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Ag | 1983 |
The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipoprotei | 1980 |
Hyperlipoproteinemia, atherosclerosis and gemfibrozil.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypo | 1982 |
Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction.
Topics: Adult; Apolipoproteins; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Gemfibrozil; Hum | 1981 |
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
Topics: Aged; Body Weight; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Gemfibroz | 1995 |
Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fibrinolysis; Gemfibrozil; Humans; Hyperlipopr | 1996 |
A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cross-Over Studies; Dietary Fats; Gemfibro | 1997 |
A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Apolipoproteins; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Double-Blind | 2002 |
The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Topics: Adult; Apolipoprotein E2; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Combined Modality Therap | 1992 |
[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia].
Topics: Adult; Aged; Bezafibrate; Cholesterol; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipoprote | 1992 |
Treatment of nephrotic hyperlipoproteinemia with gemfibrozil.
Topics: Adult; Aged; Apolipoproteins; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creat | 1989 |
Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1988 |
13 other studies available for gemfibrozil and Hyperlipoproteinemias
| Article | Year |
|---|---|
Effects of gemfibrozil on serum lipids.
Topics: Adult; Aged; Double-Blind Method; Drug Evaluation; Female; Gemfibrozil; Humans; Hyperlipoproteinemia | 1983 |
Consensus conference: Treatment of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro | 1984 |
Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment.
Topics: Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Liver; Long-Term Care; Microscopy, | 1982 |
Nutritional & pharmacologic management of hyperlipoproteinemia.
Topics: Cholesterol; Cholesterol, Dietary; Clofibrate; Dietary Fats; Gemfibrozil; Humans; Hyperlipoproteinem | 1982 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Hum | 1998 |
Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.
Topics: Adult; Aged; Analysis of Variance; Cholesterol; Combined Modality Therapy; Creatine Kinase; Drug The | 1992 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; | 1991 |
[Gemfibrozil in the treatment of hyperlipoproteinemia].
Topics: Adolescent; Adult; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Male; M | 1989 |
Lipid level alterations in the Helsinki Heart Study.
Topics: Cholesterol, HDL; Coronary Disease; Finland; Gemfibrozil; Humans; Hyperlipoproteinemias; Triglycerid | 1989 |
Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports.
Topics: Adult; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; M | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Human | 1986 |